Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients

doi:10.3760/cma.j.cn371439-20240115-00059

Abstract

Abstract:

Objective To explore the relationship between serum microRNA （miR）-24-3p， H2A histone family member X （H2AFX） and clinical pathological features and postoperative recurrence in liver cancer patients. Methods A total of 108 newly diagnosed liver cancer patients admitted to Tumor Hospital Affiliated to Nantong University from March 2018 to March 2022 were regarded as the liver cancer group. Eighty-six patients with benign liver lesions who visited our hospital during the same period were selected as the benign lesion group， and 64 healthy individuals who underwent physical examinations were selected as the control group. Quantitative real-time PCR method was applied to detect and analyze the levels of serum miR-24-3p and H2AFX mRNA in each group. The serum miR-24-3p and H2AFX levels in patients with recurrent and non-recurrent liver cancer were compared， and the comparison of clinicopathological characteristics of patients with liver cancer with different serum miR-24-3p and H2AFX levels was conducted. Logistic regression was applied to analyze the risk factors affecting postoperative recurrence in liver cancer patients. Results To the end of follow-up， of the 108 patients with liver cancer， 46 relapsed. The serum miR-24-3p levels in control group， benign lesion group， and liver cancer group were 1.01±0.23， 0.79±0.21 and 0.55±0.13， respectively， with a statistically significant difference （F=125.86， P<0.001）， serum miR-24-3p level in benign lesion group and liver cancer group was lower than that in control group （both P<0.05）， and serum miR-24-3p level in liver cancer group was lower than that in benign lesion group （P<0.05）. The serum H2AFX mRNA levels in control group， benign lesion group， and liver cancer group were 1.02±0.25， 1.27±0.31 and 1.59±0.37， respectively， with a statistically significant difference （F=65.40， P<0.001）， serum miR-24-3p level in benign lesion group and liver cancer group were higher than that in control group （both P<0.05）， and serum miR-24-3p level in liver cancer group was higher than that in benign lesion group （P<0.05）. There were statistically significant differences in TNM stage （χ²=7.85， P=0.005； χ²=6.32， P=0.012） and differentiation degree （χ²=11.59， P=0.001； χ²=9.92， P=0.002） between patients with high and low level of miR-24-3p and H2AFX. Compared with the non-relapsed patients， the serum miR-24-3p level was significantly lower （0.44±0.12 vs. 0.64±0.14） and the H2AFX level was significantly higher （1.87±0.42 vs. 1.38±0.33） among the relapsed patients， with statistically significant differences （t=7.79， P<0.001； t=6.79， P<0.001）. Univariate analysis showed that TNM stage （OR=1.57， 95%CI： 1.05-2.35， P=0.029）， differentiation degree （OR=2.20， 95%CI： 1.20-4.02， P=0.011）， miR-24-3p level （OR=0.66， 95%CI： 0.45-0.95， P=0.026）， H2AFX level （OR=1.73， 95%CI： 1.14-2.60， P=0.009） were all influential factors for postoperative recurrence in liver cancer patients. Multifactorial analysis showed that TNM stage （OR=2.10， 95%CI： 1.14-3.86， P=0.017）， differentiation degree （OR=1.58， 95%CI： 1.12-2.23， P=0.009）， miR-24-3p level （OR=0.76， 95%CI： 0.63-0.92， P=0.005）， H2AFX level （OR=1.90， 95%CI： 1.20-2.99， P=0.006） were the independent influencing factors of postoperative recurrence in liver cancer patients. Conclusion There are statistically significant differences in tumor TNM stage and differentiation degree among liver cancer patients with different serum miR-24-3p and H2AFX levels， and serum miR-24-3p and H2AFX levels are the influencing factors for postoperative recurrence in liver cancer patients.

Key words: Liver neoplasms, Serum, Recurrence, MicroRNA-24-3p, H2A histone family member X

Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.

Figures/Tables 4

References 17

[1]	Foda ZH, Annapragada AV, Boyapati K, et al. Detecting liver cancer using cell-free DNA fragmentomes[J]. Cancer Discov, 2023, 13(3): 616-631. DOI: 10.1158/2159-8290.CD-22-0659.
[2]	Ding JL, Wen ZL. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database[J]. BMC Cancer, 2021, 21(1): 1157. DOI: 10.1186/s12885-021-08904-3. pmid: 34715816
[3]	Nevola R, Ruocco R, Criscuolo L, et al. Predictors of early and late hepatocellular carcinoma recurrence[J]. World J Gastroenterol, 2023, 29(8): 1243-1260. DOI: 10.3748/wjg.v29.i8.1243.
[4]	Zhang QW, Zhang Y, Chen YQ, et al. A novel mTORC1/2 inhibitor (MTI-31) inhibits tumor growth, epithelial-mesenchymal transition, metastases, and improves antitumor immunity in preclinical models of lung cancer[J]. Clin Cancer Res, 2019, 25(12): 3630-3642. DOI: 10.1158/1078-0432.CCR-18-2548. pmid: 30796032
[5]	Sun YF, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma[J]. Cell, 2021, 184(2): 404-421.e16. DOI: 10.1016/j.cell.2020.11.041. pmid: 33357445
[6]	Ge XL, Li GY, Jiang L, et al. Long noncoding RNA CAR10 promotes lung adenocarcinoma metastasis via miR-203/30/SNAI axis[J]. Oncogene, 2019, 38(16): 3061-3076. DOI: 10.1038/s41388-018-0645-x. pmid: 30617305
[7]	Jing PY, Xie NL, Zhao N, et al. miR-24-3p/KLF8 signaling axis contributes to LUAD metastasis by regulating EMT[J]. J Immunol Res, 2020, 2020: 4036047. DOI: 10.1155/2020/4036047.
[8]	Al-Harazi O, Kaya IH, Al-Eid M, et al. Identification of gene signature as diagnostic and prognostic blood biomarker for early hepatocellular carcinoma using integrated cross-species transcriptomic and network analyses[J]. Front Genet, 2021, 12: 710049. DOI: 10.3389/fgene.2021.710049.
[9]	谢俊, 梁先春, 黄绪兰, 等. 肝癌患者血清VEGF、bFGF水平与癌组织微血管密度及介入术后早期复发的相关性[J]. 新疆医科大学学报, 2023, 46(8): 1056-1061, 1067. DOI: 10.3969/j.issn.1009-5551.2023.08.013.
[10]	Wang DY, Zheng XH, Fu BQ, et al. Hepatectomy promotes recurrence of liver cancer by enhancing IL-11-STAT3 signaling[J]. EBioMedicine, 2019, 46: 119-132. DOI: 10.1016/j.ebiom.2019.07.058. pmid: 31375423
[11]	Özdemir BH. Tumor microenvironment: necroptosis switches the subtype of liver cancer while necrosis promotes tumor recurrence and progression[J]. Exp Clin Transplant, 2023, 21(4): 291-298. DOI: 10.6002/ect.2021.0457.
[12]	Lee SS, Cheah YK. The interplay between microRNAs and cellular components of tumour microenvironment (TME) on non-small-cell lung cancer (NSCLC) progression[J]. J Immunol Res, 2019, 2019: 3046379. DOI: 10.1155/2019/3046379.
[13]	赵孝亮, 李君艳, 陈国荣. miRNA在恶性肿瘤诊断中的作用[J]. 河南大学学报(自然科学版), 2023, 53(5): 584-589. DOI: 10.15991/j.cnki.411100.2023.05.007.
[14]	Ma HL, Liu C, Zhang ST, et al. miR-328-3p promotes migration and invasion by targeting H2AFX in head and neck squamous cell carcinoma[J]. J Cancer, 2021, 12(21): 6519-6530. DOI: 10.7150/jca.60743. pmid: 34659543
[15]	Hu HL, Zhong T, Jiang SW. H2AFX might be a prognostic biomarker for hepatocellular carcinoma[J]. Cancer Rep (Hoboken), 2023, 6(1): e1684. DOI: 10.1002/cnr2.1684.
[16]	Liu T, Wu H, Qi J, et al. Seven immune-related genes prognostic power and correlation with tumor-infiltrating immune cells in hepatocellular carcinoma[J]. Cancer Med, 2020, 9(20): 7440-7452. DOI: 10.1002/cam4.3406.
[17]	海丽达·马克西, 杨芳, 艾克热木·木沙. 口腔鳞状细胞癌组织中IDO1、KYNU表达情况与临床病理特征及预后的关系[J]. 国际检验医学杂志, 2024, 45(6): 671-675. DOI: 10.3969/j.issn.1673-4130.2024.06.007.

基因	正向引物	反向引物
miR-24-3p	5’-TTTGGCTCAGTTCAGCAG-3’	5’-TTTGGCACTAGCACATT-3’
H2AFX	5’-AATCTAGATCCCTTCCAGCAAACTCAAC-3’	5’-AATCTAGAAACTCCCCAATGCCTAAGGT-3’
U6	5’-CTCAGAGCGTGGTTCTCCGTCAC-3’	5’-TATAAATCTTTACCCTGTTGGAGT-3’
GAPDH	5’-ACAGTCAGCCGCATCTTCTT-3’	5’-GACAAGCTTCCCGTTCTCAG-3’

组别	miR-24-3p	H2AFX
对照组（n=64）	1.01±0.23	1.02±0.25
良性病变组（n=86）	0.79±0.21^a	1.27±0.31^a
肝癌组（n=108）	0.55±0.13^ab	1.59±0.37^ab
F值	125.86	65.40
P值	<0.001	<0.001

临床病理特征	miR-24-3p		χ²值	P值	H2AFX		χ²值	P值
临床病理特征	高水平（n=50）	低水平（n=58）	χ²值	P值	高水平（n=57）	低水平（n=51）	χ²值	P值
性别
男	24（48.00）	31（53.45）	0.32	0.572	25（43.86）	30（58.82）	2.41	0.120
女	26（52.00）	27（46.55）	0.32	0.572	32（56.14）	21（41.18）	2.41	0.120
年龄（岁）
≥50	27（54.00）	30（51.72）	0.06	0.813	31（54.39）	26（50.98）	0.13	0.723
<50	23（46.00）	28（48.28）	0.06	0.813	26（45.61）	25（49.02）	0.13	0.723
肿瘤最大径（cm）
≥5	17（34.00）	26（44.83）	1.31	0.252	26（45.61）	17（33.33）	1.69	0.193
<5	33（66.00）	32（55.17）	1.31	0.252	31（54.39）	34（66.67）	1.69	0.193
肿瘤数量
单发	26（52.00）	32（55.17）	0.11	0.742	34（59.65）	24（47.06）	1.72	0.190
多发	24（48.00）	26（44.83）	0.11	0.742	23（40.35）	27（52.94）	1.72	0.190
Child-Pugh分级
A级	27（54.00）	33（56.90）	0.09	0.763	32（56.14）	28（54.90）	0.02	0.897
B级	23（46.00）	25（43.10）	0.09	0.763	25（43.86）	23（45.10）	0.02	0.897
TNM分期
Ⅰ~Ⅱ	41（82.00）	33（56.90）	7.85	0.005	33（57.89）	41（80.39）	6.32	0.012
Ⅲ	9（18.00）	25（43.10）	7.85	0.005	24（42.11）	10（19.61）	6.32	0.012
分化程度
低分化	10（20.00）	30（51.72）	11.59	0.001	29（50.88）	11（21.57）	9.92	0.002
中高分化	40（80.00）	28（48.28）	11.59	0.001	28（49.12）	40（78.43）	9.92	0.002
甲胎蛋白（ng/ml）
<400	27（54.00）	25（43.10）	1.28	0.258	27（47.37）	25（49.02）	0.03	0.864
≥400	23（46.00）	33（56.90）	1.28	0.258	30（52.63）	26（50.98）	0.03	0.864